Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Achim Steup
Observed names:
A Steup,
A. Steup,
Steup, Achim
Institution:
Astellas Pharma (United States)
Observed institutions:
TU Dortmund University,
Institut für Hygiene und Umwelt,
Universitätsklinikum Aachen,
Astellas Pharma (Netherlands),
Astellas Pharma (United States),
Janssen Research & Development (United States),
RWTH Aachen University,
Grünenthal Group (Germany)
show all 8
OpenAlex ID:
A5064903552
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study
2010
·
Robert Buynak
, Douglas Y Shapiro
, et al.
·
Expert Opinion on Pharmacotherapy
·
267
Efficacy and Safety of Tapentadol Extended Release Compared with Oxycodone Controlled Release for the Management of Moderate to Severe Chronic Pain Related to Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo- and Active-Controlled Phase III Study
2010
·
Marc Afilalo
, Mila S. Etropolski
, et al.
·
Clinical Drug Investigation
·
255
Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain
2010
·
Bernd Lange
, Brigitte Kuperwasser
, et al.
·
Advances in Therapy
·
186
Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain
2010
·
James E. Wild
, Stefan Grond
, et al.
·
Pain Practice
·
185
Single Dose Analgesic Efficacy of Tapentadol in Postsurgical Dental Pain: The Results of a Randomized, Double-Blind, Placebo-Controlled Study
2008
·
Regina Kleinert
, Claudia Lange
, et al.
·
Anesthesia & Analgesia
·
108
The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery
2008
·
Jens-Ulrich Stegmann
, Horst Weber
, et al.
·
Current Medical Research and Opinion
·
99
Indoor environment and respiratory symptoms in children living in the Dutch–German borderland
2005
·
M. Mommers
, A.W. Jongmans-Liedekerken
, et al.
·
International Journal of Hygiene and Environmental Health
·
37
Tapentadol prolonged-release for moderate-to-severe chronic osteoarthritis knee pain: a double-blind, randomized, placebo- and oxycodone controlled release-controlled study
2017
·
Alain Serrie
, Bernd Lange
, et al.
·
Current Medical Research and Opinion
·
35
Efficacy and safety of mirabegron in children and adolescents with neurogenic detrusor overactivity: An open‐label, phase 3, dose‐titration study
2021
·
Małgorzata Baka‐Ostrowska
, David T. Bolong
, et al.
·
Neurourology and Urodynamics
·
32
Cardiovascular Risk in Users of Mirabegron Compared with Users of Antimuscarinic Treatments for Overactive Bladder: Findings from a Non-Interventional, Multinational, Cohort Study
2021
·
Veena Hoffman
, Jesper Hallas
, et al.
·
Drug Safety
·
27
PDF
What are the additional signs and symptoms in patients with detrusor underactivity and coexisting detrusor overactivity?
2018
·
Andrew Gammie
, Mathilde Kaper
, et al.
·
Neurourology and Urodynamics
·
23
Signs and symptoms that distinguish detrusor underactivity from mixed detrusor underactivity and bladder outlet obstruction in male patients
2018
·
Andrew Gammie
, Mathilde Kaper
, et al.
·
Neurourology and Urodynamics
·
19
Direct conversion from tramadol to tapentadol prolonged release for moderate to severe, chronic malignant tumour‐related pain
2016
·
H.G. Kress
, E.D. Koch
, et al.
·
European Journal of Pain
·
18
PDF
Nasal Function in Self-Reported Chemically Intolerant Individuals
2002
·
Gerhard Andreas Wiesmüller
, Christoph van Thriel
, et al.
·
Archives of Environmental Health An International Journal
·
18
Safety and efficacy of an α1‐blocker plus mirabegron compared with an α1‐blocker plus antimuscarinic in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia and overactive bladder: A systematic review and network meta‐analysis
2024
·
Sender Herschorn
, Tufan Tarcan
, et al.
·
Neurourology and Urodynamics
·
16
PDF
Predicting Mirabegron Treatment Response in Patients with Overactive Bladder: A Post Hoc Analysis of Data from Clinical Trials
2023
·
Rano Matta
, Refik Saskin
, et al.
·
European Urology Focus
·
7
Flow time and voiding time – definitions and use in identifying detrusor underactivity
2016
·
Andrew Gammie
, Satoshi Yoshida
, et al.
·
Neurourology and Urodynamics
·
6
(312/776)
2006
·
H. Weber
, C. Hallmann
, et al.
·
Journal of Pain
·
5
Inner Room-Questionnaire for the German-speaking area
1999
·
Gerhard Andreas Wiesmüller
, Achim Steup
, et al.
·
Zentralblatt für Hygiene und Umweltmedizin
·
5
328 Efficacy and Safety of Tapentadol Extended Release Versus Oxycodone Controlled Release in Opioid-naive and Opioid-experienced Patients With Chronic Pain Associated With Osteoarthritis of the Knee
2009
·
M. Etropolski
, B. Lange
, et al.
·
Osteoarthritis and Cartilage
·
4
[Simple photometric method for the determination of L-dopa and carbidopa in drug preparations].
1986
·
A Steup
, J Metzner
, et al.
·
Die Pharmazie
·
4
708 Results of a Randomized, Double‐blind, Placebo‐and Active‐controlled Trial of Tapentadol Extended Release for Chronic Low Back Pain
2009
·
D.Y. Shapiro
, R. Buynak
, et al.
·
European Journal of Pain
·
3
Interreg II - Euregionale Untersuchungen zu chronischen Atemwegserkrankungen bei Kindern im deutsch- niederländischen Grenzraum
2001
·
M Weishoff-Houben
, R Derkx
, et al.
·
Das Gesundheitswesen
·
3
292 Tapentadol Prolonged Release (pr) for Painful Diabetic Peripheral Neuropathy (dpn): Efficacy and Safety by Prior Opioid Experience and Dose Category
2010
·
D.Y. Shapiro
, M. Etropolski
, et al.
·
European Journal of Pain Supplements
·
2
Osteoarthritis [119-126]: 119. The Value of HFE Genotyping in Exceptional Osteoarthritis
2010
·
S. Arthanari
, M. Nisar
, et al.
·
Rheumatology
·
2
Show more works
View as search
Works count:
44
Citation count:
1,380
H-index:
15
I10-index:
15
Year
Topic
Type